These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24888255)

  • 1. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.
    Heise T; Nosek L; Roepstorff C; Chenji S; Klein O; Haahr H
    Diabetes Ther; 2014 Jun; 5(1):255-65. PubMed ID: 24888255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
    Haahr H; Fita EG; Heise T
    Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status.
    Christiansen JS; Home P; Kumar A
    Expert Rev Endocrinol Metab; 2016 Mar; 11(2):103-111. PubMed ID: 30058868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Clinical Profile of IDegAsp.
    Unnikrishnan AG; Singh AK; Modi KD; Saboo B; Garcha SC; Rao PV
    J Assoc Physicians India; 2015 May; 63(5 Suppl):15-20. PubMed ID: 26548030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
    Biester T; Danne T; Bläsig S; Remus K; Aschemeier B; Kordonouri O; Bardtrum L; Haahr H
    Pediatr Diabetes; 2016 Dec; 17(8):642-649. PubMed ID: 26782928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
    Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
    Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
    Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
    Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.
    Hirose T; Awata T; Yamamoto Y; Hemmingsen MP
    Expert Opin Biol Ther; 2018 Jan; 18(1):77-85. PubMed ID: 29017373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
    Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
    Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
    Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
    Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
    Heise T; Tack CJ; Cuddihy R; Davidson J; Gouet D; Liebl A; Romero E; Mersebach H; Dykiel P; Jorde R
    Diabetes Care; 2011 Mar; 34(3):669-74. PubMed ID: 21285389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.
    Cho KY; Nakamura A; Oba-Yamamoto C; Tsuchida K; Yanagiya S; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    Diabetes Metab J; 2020 Aug; 44(4):532-541. PubMed ID: 31769240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
    Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
    Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
    Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
    Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.